AG
BIS icon

Advisor Group’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Advisor Group’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-63
Closed -$10K – 4954
2017
Q3 		$10K Buy
+63
New +$11.4K ﹤0.01% 3951

Other funds holding BIS

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return

Advisor Group's BIS Position: Q4 2017 in Review

Advisor Group sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2017, closing a stake of 63 shares — an estimated $10K sold.

Advisor Group first reported a position in BIS in Q3 2017 and held it in 1 quarter. The position peaked at $10K in Q3 2017. 11 funds tracked by Wall St. Rank hold BIS as of Q4 2017.

  • Advisor Group reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2017 after selling out during the quarter.
  • Advisor Group sold 63 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2017, an estimated $10K.
  • Advisor Group first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2017 and held it in 1 quarter.
  • Advisor Group's ProShares UltraShort NASDAQ Biotechnology position peaked at $10K in Q3 2017.
  • 11 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2017.

Based on Advisor Group's 13F filing for Q4 2017, filed 14 Feb 2018.